Search company, investor...
BioXplor company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Incubator/Accelerator - II | Alive

Total Raised


Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About BioXplor

BioXplor is an augmented intelligence platform for data-driven hypotheses generation and predictions in biomarker and drug discovery. The virtual discovery platform is built on the intersection of big data, artificial intelligence and high performance computing, and works by enabling accelerated data interpretations from unstructured literature and structured multi-omics data. In house and external projects are focused on AI-assisted biomarker discovery, molecular target identification and drug repurposing, presently in cancer and rare disease.

BioXplor Headquarters Location

9c the Bottleworks Irishtown



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioXplor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioXplor is included in 5 Expert Collections, including Digital Health.


Digital Health

21,952 items

Startups recreating how healthcare is delivered


Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

838 items


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Latest BioXplor News

8 Irish start-ups selected for EIT Health accelerator

May 23, 2022

John Kennedy Share Share 8 high-potential health innovation start-ups in Ireland secure places on seven competitive European programmes facilitated by E IT Health . EIT Health, Europe’s largest health innovation network, today announced that eight Irish biotech, digital health and medtech start-ups have been selected for seven of its highly competitive business accelerator programmes for phase-one 2022. “The selection process is highly competitive, as Irish teams, companies, and founders compete against hundreds of others across 26 countries for limited places on each of our programmes” Each business will benefit from access to a vast network of internationally renowned experts, mentors, and investors, as well as support with entering new European markets. Added value from innovation “The selection process is highly competitive, as Irish teams, companies, and founders compete against hundreds of others across 26 countries for limited places on each of our programmes,” said Marc Butterly, Business Creation Lead at EIT Health Ireland-UK. “We’re proud at EIT Health Ireland-UK to help these eight selected companies accelerate into Europe. “Navigating the right programme to apply to depends on business, product, and market factors. We work to add value to these entrepreneurs’ innovation journeys.” Kid’s Speech Labs , which has developed software to help parents track their children’s speech and language development via an app, will join 40 other European start-ups the Bridgehead programme. This helps health entrepreneurs access new European and international markets quickly, by tapping into local networks, accessing infrastructure, and understanding new regulatory systems. Bridgehead is delivered via a network of over 45 business “catalyser” organisations across Europe, for example the NHS Academic Health Science Network. EIT Health is actively seeking Ireland-based catalysers to operate within the network to avail of the benefits of international collaboration. Joining 15 other companies this year on the Start-Ups Meet Healthcare Providers programme is Akara Robotics , a Trinity College Dublin spin-out. Akara has built a fully autonomous UV disinfection robot, which reduces turnaround times for clinical settings. The programme will grant Akara direct access to key European stakeholders to test its solution at Tartu University Hospital in Estonia, helping the team fine-tune their cutting-edge innovation. BioXplor , which has developed an AI-driven data analytics platform to collect real world evidence on cancer, has been accepted onto EIT Health’s Wild Card programme. Wild Card tackles a new challenge each year and, in 2022, teams are tasked with finding solutions in the early detection of cancer, or mental health before pitching their ideas to a panel of industry leaders. Programme participants could potentially secure up to €1.5M in European funding to bring their solution to market. “The whole team at BioXplor is delighted to join Wild Card. I think we can deliver an amazing solution for prostate cancer patients,” said BioXplor CEO, Anna O’Leary. Irish health innovation businesses, such as BioXplor, will also have a spotlight at the upcoming EIT Health Summit taking place in Stockholm this week (24 – 25 May). Luminate Medical , which has developed a novel device to prevent hair loss during chemotherapy, will participate in the event’s Catapult competition for a €40,000 cash prize.

BioXplor Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioXplor Rank

  • When was BioXplor founded?

    BioXplor was founded in 2017.

  • Where is BioXplor's headquarters?

    BioXplor's headquarters is located at 9c the Bottleworks, Dublin.

  • What is BioXplor's latest funding round?

    BioXplor's latest funding round is Incubator/Accelerator - II.

  • How much did BioXplor raise?

    BioXplor raised a total of $100K.

  • Who are the investors of BioXplor?

    Investors of BioXplor include Headstart Accelerator, Merck Accelerator and Berkeley SkyDeck.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.